Prognostic Factor Analysis of Stage 4S Neuroblastoma in Infant Patients: A Single Center Study
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Sep 2019 · 1 min read
In brief
In brief
This retrospective study of 28 infants with stage 4S neuroblastoma identifies abdominal compartment syndrome and chemotherapy sensitivity as key prognostic factors, with an overall 5-year survival of 84.4%. The research provides insights into treatment approaches and outcomes for this unique metastatic disease category in infants.
Written by the GCMD Library team from the article.
Background
Stage 4S neuroblastoma is a unique category of metastatic disease in infants with a favorable outlook. The purpose of this study was to clarify the prognostic factors of patients with stage 4S neuroblastoma.
Method
Data were retrospectively collected from infant patients with stage 4S neuroblastoma in our department from May 2000 to May 2018. Patient characteristics, operative variables, perioperative outcomes, overall survival (OS), and recurrence were evaluated. Univariate and multivariate analyses were performed to identify the prognostic factors of stage 4S neuroblastoma.
Result
A total of 28 infant patients (71. 4% males) with a mean age of 3.7 ± 2.7 months were recruited. The involved metastatic sites included liver (n = 18), skin (n = 9), and bone marrow (n = 5). Nine patients received biopsy, and 14 patients underwent original lesions resection followed by postchemotherapy. Five patients accompanied with abdominal compartment syndrome (ACS) were given experiential chemotherapy. The follow-up time ranged from 12 M to 156 M, with a mean of 32 months. Twenty-two patients completed treatment and survived. Two patients were still under treatment. Four patients died, including three with ACS. No recurrence was observed. According to Kaplan–Meier method, the 5-year overall survival was 84.4%. ACS (p = 0.001) and chemotherapy sensitivity (p